EvolveMKD
Independent
Address
49 W 24th St, 7th Fl.
New York, New York 10010
Web Address
Year Founded
2014
Full-time Employees
26
Number of Clients
0
North American Revenue 2021
Full-time Employees 2021
Number of clients 2021
Offices
North America
1
Locations
Main Office - 49 w 24th Street, Floor 7, New York, NY
Executives & Senior Management
Megan Driscoll
CEO + Founder
Adeena Fried
Senior Vice President
Maggie Holmes
Senior Vice President, Digital
Senior Management
Megan Driscoll
CEO + Founder
Adeena Fried
Senior Vice President
Maggie Holmes
Senior Vice President, Digital
Alex Christian
Vice President, Research & Analytics
Sam Anderson
Vice President, Public Relations
Tabatha Roman
Vice President, Public Relations
Agency 100 Book Cover
Capabilities/Services Offered
Direct Marketing
Media Planning
Data/Analytics
New Services
In 2021, our Creative offerings have expanded to include:
Monthly Organic Social Media for various platforms
Paid Advertising
Event Collateral
A+ Pages/Landing Pages
Newsletters
Research and Analytics began offering the below:
Whitespace Analysis
Publicity Surveys Finally, we've added Controlled Media Regional Segments, Creative Campaign Development, and Executive Thought Leadership Social Strategy capabilities to our public relations and digital teams.
Client Roster
CooperCompanies - includes CooperVision, CooperSurgical, and CooperCompanies
Endo International, plc - includes Endo Aesthetics
HydraFacial, a BeautyHealth Company - includes the HydraFacial system InBrace
ISDIN Neuronetics - includes NeuroStar
Obagi - includes Clinical and Medical Skinbetter Science
Sientra Solta Medical – includes Thermage® system, Fraxel® system, Clear + Brilliant® system
Growth
2021 Growth from Existing Clients
83%
2021 Growth from New Clients
17%
Trends and Challenges
Diversity and inclusion
Talent acquisition/retention
Managing growth
Replenishing new-business pipeline
Procurement-related issues
Healthcare Marketing Trends
More personalization of communications
Need to create more/better content/experiences
Heightened focus on payers
Increased concern over drug pricing
Industry consolidation
Scrutiny around social media
Impact of empowered patients/consumers
Intensified focus on analytics/ROI/measurement
Decreased impact of sales forces
Regulatory changes
Programs that go “beyond the pill”
Evolution of EHRs
Emphasis on specialty drugs/high-science categories
Adopting a data-science culture
More digital experimentation
Seizing opportunities around cannabis
Working from home
Ongoing fallout from pandemic
